Next Article in Journal
Influence of Iron on Bone Homeostasis
Next Article in Special Issue
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Previous Article in Journal
Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis
Previous Article in Special Issue
Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
Pharmaceuticals 2018, 11(4), 106;

Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging

Department of Nuclear Medicine, School of Medicine, Rajaie Cardiovascular, Medical and Research Center & Department of Medicinal Chemistry, School of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran 1449614535, Iran
Centre for Comparative Genomics, Murdoch University, Perth 6150, Australia
Perron Institute for Neurological and Translational Science, Perth 6009, Australia
Author to whom correspondence should be addressed.
Received: 22 August 2018 / Revised: 6 October 2018 / Accepted: 10 October 2018 / Published: 15 October 2018
(This article belongs to the Special Issue Aptamer-Based Diagnostics and Therapeutics)
Full-Text   |   PDF [5934 KB, uploaded 17 October 2018]   |  


Aptamers are short single-stranded DNA or RNA oligonucleotide ligand molecules with a unique three-dimensional shape, capable of binding to a defined molecular target with high affinity and specificity. Since their discovery, aptamers have been developed for various applications, including molecular imaging, particularly nuclear imaging that holds the highest potential for the clinical translation of aptamer-based molecular imaging probes. Their easy laboratory production without any batch-to-batch variations, their high stability, their small size with no immunogenicity and toxicity, and their flexibility to incorporate various functionalities without compromising the target binding affinity and specificity make aptamers an attractive class of targeted-imaging agents. Aptamer technology has been utilized in nuclear medicine imaging techniques, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET), as highly sensitive and accurate biomedical imaging modalities towards clinical diagnostic applications. However, for aptamer-targeted PET and SPECT imaging, conjugation of appropriate radionuclides to aptamers is crucial. This review summarizes various strategies to link the radionuclides to chemically modified aptamers to accomplish aptamer-targeted PET and SPECT imaging. View Full-Text
Keywords: aptamers; aptamer-targeted imaging; molecular imaging; aptamer-radiolabeling aptamers; aptamer-targeted imaging; molecular imaging; aptamer-radiolabeling

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hassanzadeh, L.; Chen, S.; Veedu, R.N. Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging. Pharmaceuticals 2018, 11, 106.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top